Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell therapy
V. Bhatia, N. V. Kamat, T. E. Pariva…·J. K. Lee
This study develops STEAP1 CAR T cell therapy for advanced prostate cancer, showing potent antitumor activity and safety in preclinical models, but also identifies antigen loss as a resistance mechanism.